Rationale: Mammalian cardiomyocytes withdraw from the cell cycle during early postnatal development, which significantly limits the capacity of the adult mammalian heart to regenerate after injury. The regulatory mechanisms that govern cardiomyocyte cell cycle withdrawal and binucleation are poorly understood.
T he adult mammalian heart is one of the least regenerative organs in the body. In contrast, the neonatal mammalian heart possesses a remarkable capacity for cardiac regeneration. 1 Importantly, the neonatal mouse heart's ability to regenerate after injury is lost by 7 days of age, a time point that coincides with the onset of cardiomyocyte proliferative arrest and binucleation in rodents. 2, 3 Genetic fate-mapping experiments in the neonatal mouse 1 and adult zebrafish 4, 5 suggest that the majority of regenerated cardiomyocytes are derived from preexisting cardiomyocytes through cell division rather than activation of an undifferentiated stem or progenitor cell. Therefore, an understanding of the mechanisms that regulate the postnatal transition of the mammalian heart toward cell cycle arrest is of fundamental importance.
Cardiomyocytes undergo extensive proliferation during embryogenesis but withdraw from the proliferative cell cycle shortly after birth. 6 Beginning at postnatal day 5 in rodents, the majority of cardiomyocytes undergo a final round of DNA replication and karyokinesis in the absence of cytokinesis, which results in binucleation of approximately 90% of cardiomyocytes by the second week of postnatal life. 2, 3 Although recent studies suggest that adult cardiomyocytes can reenter the cell cycle and proliferate in response to certain mitogens (eg, fibroblast growth factor, periostin, neuregulin), [7] [8] [9] it appears that this proliferative potential is restricted to a small proportion of mononucleated cardiomyocytes. 7 Although postnatal activation of tumor suppressor pathways appears to be an important mechanism for cardiomyocyte terminal differentiation, 10 the molecular mechanisms that regulate postnatal cardiomyocyte binucleation and mitotic arrest remain one of the most poorly understood aspects of cardiac biology.
Recently, microRNAs (miRNAs, or miRs) have emerged as important regulators of almost every aspect of cardiac biology, 11 including cardiomyocyte proliferation. 12, 13 miR-NAs are small (Ϸ22 nucleotides) noncoding RNAs that induce posttranscriptional repression of gene expression by binding to target recognition sequences predominantly located within the 3Ј untranslated region (3ЈUTR) of target mRNAs. 11 Targeting of an miRNA to its mRNA target is dependent on the "seed" sequence, which spans bases 2 to 8 of the 5Ј portion of a mature miRNA. Individual miRNAs can target numerous mRNAs, and it is becoming increasingly evident that miRNAs often exert their actions by modestly repressing the expression of many mRNAs with related biological functions. 11 Furthermore, some of the most abundant miRNAs in the heart belong to large miRNA "seed" families, comprising multiple miRNAs that share a high degree of sequence homology and a common "seed" region. 14 Therefore, multiple miRNAs with related functions within an miRNA family have the potential to redundantly regulate complex biological processes by targeting multiple genes in a common pathway. Despite the vast regulatory potential of miRNAs and their involvement in various aspects of cell cycle control, little is known about how miRNAs might contribute to postnatal maturation and terminal differentiation of cardiomyocytes.
In an attempt to identify miRNAs involved in cardiomyocyte mitotic arrest, we examined the developmental expression pattern of miRNAs in the heart during the postnatal transition toward binucleation and cell cycle withdrawal. Here, we describe a collection of miRNAs that are dysregulated in the heart between postnatal days 1 and 10 (P1 and P10, respectively). Interestingly, miR-195, a member of the miR-15 family, was the most highly upregulated miRNA during this period. We show that premature overexpression of miR-195 in the embryonic heart causes a spectrum of congenital heart abnormalities associated with premature cell cycle arrest. miR-195 negatively regulates the expression of a number of cell cycle genes, including checkpoint kinase 1 (Chek1), which was found to be enriched within the RNAinduced silencing complex (RISC) of neonatal miR-195 transgenic hearts in vivo. Postnatal inhibition of the miR-15 family with anti-miRs was associated with an increased number of mitotic cardiomyocytes and derepression of several miR-15 family target genes, including Chek1. These results reveal that upregulation of the miR-15 family provides a previously unappreciated layer of regulatory control that contributes to postnatal cardiomyocyte cell cycle withdrawal after birth.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Experimental Animals and Tissue Collection
All protocols were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center. C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were used for miRNA expression profiling during postnatal development. For RNA analysis, atrial tissues were removed from ventricles (septum intact), and ventricles were blotted and weighed before being snap-frozen in liquid nitrogen for storage at Ϫ80°C.
Generation of ␤-Myosin Heavy Chain-miR-195 Transgenic Mice
A mouse genomic fragment flanking miR-195 was subcloned into a cardiac-specific expression plasmid containing 7 kb of upstream regulatory sequence from the ␤-myosin heavy chain (MHC) promoter and human growth hormone poly(A) ϩ signal. 15 Transgenic mice were generated by pronuclear injection with standard procedures and maintained on a mixed genetic background.
In Vivo Delivery of Synthetic Locked Nucleic Acid-Anti-miR Oligonucleotides to Neonatal Mice
Locked nucleic acid (LNA)-modified anti-miRs directed against the mature miR-15b and miR-16 sequences were synthesized as unconjugated and fully phosphorothiolated oligonucleotides (miRagen Therapeutics, Boulder, CO). The LNA-anti-miRs were designed to perfectly complement 16 nucleotides of the mature miR-15b and miR-16 sequences, respectively (sequences shown in Online Table  II) . A control LNA-anti-miR was also used that contained the same LNA/DNA chemical composition as the anti-15/16 oligonucleotides but was designed to target an miRNA sequence that is unique to Caenorhabditis elegans and is not expressed in mammals. Neonatal mice (CD-1/ICR strain, Charles River Laboratories, Wilmington, MA) received control oligonucleotide, anti-miR-15b, anti-miR-16, or a combination of anti-miR-15b/16 at a dose of 25 mg/kg body weight via subcutaneous injection once per day at postnatal days 2, 3, and 4 (P2 through P4). Hearts were harvested at P12 (ie, 10 days after the first treatment) for assessment of miRNA knockdown, target gene regulation, and histology.
Histological Analysis
Hearts used for histology were briefly rinsed in PBS, fixed in 4% paraformaldehyde overnight, and then transferred to 50% ethanol until they were embedded in paraffin. Sections (5 m thickness) were processed for staining with hematoxylin and eosin and Masson trichrome according to standard procedures.
Immunofluorescence
All immunofluorescence was performed on paraffin sections as described previously. 1 Antibody details are available in the Online Methods.
RNA Analysis
Total RNA was extracted from mouse hearts with TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Details of real-time polymerase chain reaction (PCR) analysis and Northern blotting are provided in the Online Methods. Real-time PCR primers and Northern probes are provided in Online Tables III and IV, respectively. 
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Microarray for mRNAs
Microarray analysis was performed on RNA samples extracted from P1 cardiac ventricles from ␣-MHC-miR-195 transgenic and wildtype mice. 17 Microarray analysis was performed by the University of Texas Southwestern Microarray Core Facility with the Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA) as described previously. 18 A fold-change cutoff of 1.5 was considered significant.
RISC RNA Sequencing
RISC RNA sequencing experiments were conducted on argonaute-2 immunoprecipitates from P1 cardiac ventricles from ␣-MHC-miR-195 transgenic and wild-type (WT) mice (nϭ3 WT and nϭ4 transgenic mice), as described previously. 19 A fold enrichment cutoff of Ͼ2.0 was considered significant. MiR-15 family binding sites were identified in putative target transcripts by cross-referencing to 3 different computational algorithms for prediction of miRNA 3ЈUTR binding sites (TargetScan 5.1, miRanda 3.0, and PITA v6.0).
Gene Ontology Cluster Analysis
Gene ontology analysis was performed for genes that were significantly regulated in miR-195 transgenic hearts (Ͼ1.5-fold) and for genes that were enriched in miR-195 transgenic RISC (Ͼ2-fold). Gene ontology analysis was conducted with the Database for Annotation, Visualization, and Integrated Discovery (DAVID) functional annotation tool. DAVID analysis was performed with "high" classification stringency and a probability value cutoff of 0.001.
Cell Culture, Transfection, and Luciferase Assays
A 1948-bp genomic fragment of the Chek1 3ЈUTR encompassing the miR-15 family binding site was amplified by PCR and ligated into the firefly luciferase (f-luc) reporter construct (pMIR-REPORTTM; Ambion, Austin, TX). The seed region of the miR-195 target site in the Chek1 3ЈUTR was mutated with the QuickChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA). Primer sequences are provided in Online Table V .
Results
Identification of miRNAs Regulated During Postnatal Heart Development
To identify miRNAs involved in the postnatal onset of cardiomyocyte binucleation and cell cycle withdrawal, we compared miRNA expression profiles in mouse cardiac ventricles at P1 and P10. A total of 71 miRNAs were differentially regulated during this developmental transition (41 miRNAs showed increased expression between P1 and P10 and 30 showed decreased expression between P1 and P10; Figure 1A ; Online Table I ). One of the most robustly downregulated miRNAs between P1 and P10 was miR-208b, located within an intron of the Myh7 gene, 20 which is well known to be downregulated after birth. 21 Interestingly, multiple large miRNA families were upregulated between P1 and P10, including the miR-15, miR-30, and let-7 families ( Figure  1A ; Online Table I ). A subset of miRNAs from the array data were confirmed by real-time PCR analysis with probes specific for the mature miRNA sequences in the mouse ( Figure 1B ).
Multiple miR-15 Family Members Are Upregulated During Postnatal Heart Development
The most highly upregulated miRNA between P1 and P10 was miR-195 ( Figure 1B) , a member of the miR-15 family. The miR-15 family consists of 6 highly conserved miRNAs, which are clustered on 3 separate chromosomes (Online Figure IA ). All members of the miR-15 family (miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195, and miR-497) share a common seed region, with varying degrees of sequence homology in the nonseed region of the mature miRNA (Online Figure I, B ). Northern blot analysis of multiple adult mouse tissues demonstrated miR15a, miR-16, miR-195, and miR-497 expression in most adult tissues, including the heart (Online Figure II, A) . The precise time course of miR-15 family upregulation was further examined in mouse hearts harvested at multiple time points between P0 and P84. Real-time PCR analysis demonstrated that miR-195, miR-497, miR-15a, and miR-16 were all upregulated in mouse cardiac ventricles between P7 and P14 ( Figure 1C ), a time point that coincides with the onset of cardiomyocyte binucleation. 2, 3 Upregulation of miR-195, miR-497, and miR-16 between P7 and P14 was confirmed by Northern blot (Online Figure II, B ). To examine whether the postnatal upregulation of miR-15 family members occurred in the myocyte population or another cell type, we isolated embryonic and neonatal rat cardiomyocytes between embryonic day 19 and P14 and profiled miR-15 family expression. Real-time PCR analysis confirmed that multiple miR-15 family members were upregulated in rodent ventricular cardiomyocytes between P7 and P14 ( Figure 1D ).
Overexpression of miR-195 in the Developing Heart Causes Congenital Heart Abnormalities Associated With Premature Cell Cycle Arrest
To determine whether upregulation of the miR-15 family plays a role in arresting cardiomyocyte proliferation, we generated transgenic mice that overexpressed miR-195 in the embryonic heart under the control of the ␤-MHC promoter. Because overexpression of miR-195 caused perinatal cardiomyopathy and early lethality in 2 independent transgenic founders (Online Figure III) , we focused our analyses on a third transgenic line, which was viable. We were unable to obtain additional viable lines of ␤-MHC-miR-195 transgenic mice despite multiple rounds of pronuclear injection, which suggests that expression of miR-195 above a certain threshold is lethal and most likely reflects the potent antiproliferative activity of this miRNA (see below). Northern blot and real-time PCR analysis showed miR-195 to be overexpressed in transgenic cardiac ventricles Ϸ45-fold above WT levels (Figure 2A ). Histological analysis of transgenic hearts between P1 and P3 revealed that mice that overexpressed miR-195 developed congenital heart defects, including ventricular septal defects (4 of 18 analyzed; Figure 2B ) and ventricular hypoplasia, which appeared to predominantly affect the right ventricle (2 of 18 analyzed; Figure 2B ). On average, neonatal transgenic hearts displayed a significant reduction in ventricle weight (Ϸ16%) and ventricle weightto-body weight ratio (Ϸ10%) at P1 compared with WT littermates ( Figure 2C ). Interestingly, transgenic mice developed a slow-onset cardiomyopathy and died prematurely (Online Figure IV, A) , beginning at 5 to 6 months of age, with evidence of cardiac enlargement and dilation apparent on necropsy (Online Figure IV, B) . Because we did not observe ventricular septal defects in ␤-MHC-miR-195 transgenic mice that survived to adulthood, we assume that these ventricular septal defects either closed spontaneously during early postnatal life or that these mice died soon after birth.
␤-MHC-miR-195 transgenic hearts were examined at P1 for evidence of defective mitosis, increased apoptosis, or reduced cell size, all of which could potentially explain why these hearts are smaller at birth. We did not detect any significant differences in cell size or apoptosis between transgenic hearts and WT littermates at P1 (Online Figure V) . In contrast, a marked reduction (Ϸ3-fold) in the number of cells undergoing mitosis and an increased proportion of multinucleated myocytes (Ϸ3-fold) were noted in transgenic hearts at P1 ( Figures 3A and 3B) . These data indicate that overexpression of miR-195 in vivo inhibits cardiomyocyte mitotic progression and induces premature cell cycle arrest.
To test the direct effects of miR-195 on cardiomyocyte proliferation, we infected cultured neonatal rat cardiomyocytes with an adenovirus that expressed miR-195 (Ad195). 17 miR-195 expression levels were titrated to match endogenous levels of miR-195 in the P14 heart (Online Figure VI, A) . Overexpression of miR-195 in cultured neonatal cardiomyocytes was associated with cellular hypertrophy (Online Figure VI, B) , as reported previously. 17 In addition, we found that a greater proportion of neonatal cardiomyocytes that overexpressed miR-195 were binucleate (Online Figure VI, B and C) . Cell cycle profile analysis indicated that neonatal cardiomyocytes that expressed miR-195 accumulated in the G2 phase (Online Figure VI, D) , consistent with a block in the G2/M phase transition and defective mitotic progression. Similar results were obtained in the proliferative myoblastic cell line H9c2, which also displayed an accumulation of cells in the G2 phase after overexpression of miR-195 (Online Figure VI, E) .
miR-195 Negatively Regulates the Expression of Cell Cycle Genes
Global changes in the transcriptional profile of neonatal hearts overexpressing miR-195 were assessed by microarray. Quantification of pH3 staining in WT and TG hearts at P1 is shown (right). Values are presented as meanϮSEM; *PϽ0.05. B, Sections from 1-day-old WT and TG hearts stained with wheat germ agglutinin (WGA) and Hoechst 33342 to label cell membranes and nuclei, respectively. Arrows denote multinucleated cells. Scale barϭ20 m. Quantification of the percentage of multinucleated cells in WT and TG hearts at P1 is shown (right). Values are presented as meanϮSEM, *PϽ0.05. C, Ontology analysis of genes differentially regulated in miR-195 transgenic hearts at P1. Genes that were either repressed (green) or induced (red) by miR-195 overexpression were clustered on the basis of shared ontology by use of the DAVID algorithm. A corrected PϽ0.001 was considered significant.
We identified 228 genes that were downregulated in transgenic cardiac ventricles at P1 and 100 genes that were upregulated at this time point (Online Figure VII, A) . Among the transcripts that were significantly repressed in transgenic ventricles at P1, gene ontology cluster analysis revealed a striking enrichment for genes involved in mitosis and various aspects of cell division ( Figure 3C ). Thirty-nine of the genes that were downregulated in transgenic ventricles (Ϸ17%) contained predicted miR-15 family binding sites within their 3ЈUTRs, but there was little overlap between different target prediction algorithms (Online Figure VII, B) .
In an attempt to identify direct in vivo targets of miR-195, we used a recently described method for context-specific detection of miRNA targets by RNA-induced silencing complex RNA sequencing (RISC-seq). 19 Using next-generation massively parallel sequencing of unamplified mRNAs isolated from argonaute-2 immunoprecipitates from transgenic and WT cardiac ventricles at P1, we were able to identify a number of transcripts enriched (Ͼ2-fold) within the miR-195 RISCome (Online Figure VII, C and D) . Gene ontology cluster analysis of transcripts that were overrepresented within the miR-195 RISCome demonstrated significant enrichment for genes involved in the regulation of the mitotic cell cycle, chromosome condensation, and the cellular response to DNA damage ( Figure  4A) . Among the 547 genes enriched (Ͼ2-fold) within the miR-195 RISCome, 128 (Ϸ23%) contained predicted miR-15 family binding sites within their 3ЈUTRs. Following DAVID gene ontology cluster analysis, we identified 20 genes that were enriched within the miR-195 RISCome that are known regulators of the mitotic cell cycle (Online Figure VIII, A) . Although 5 of these mitotic genes (Chek1, Cdc2a, Birc5, Nusap1, and Spag5) contained predicted miR-15 family binding sites within their 3ЈUTRs (Online Figure VIII, A) , the Chek1 binding site was the only one conserved from mice to humans (Online Figure  VIII, A and B ). Furthermore, real-time PCR analysis indicated that Chek1, Cdc2a, Birc5, Nusap1, and Spag5 were all robustly downregulated in the heart between P7 and P14, which was inversely correlated with the endogenous expression pattern of miR-195 (Online Figure IX and data not shown). Real-time PCR analysis demonstrated an Ϸ20% to 40% reduction in the expression levels of Chek1, Cdc2a, Birc5, Nusap1, and Spag5 in ␤-MHC-miR-195 transgenic hearts at P1 ( Figure 4B ), which indicates that miR-195 modestly represses the expression of these cell cycle genes in vivo.
We next conducted 3ЈUTR luciferase reporter assays to determine whether miR-195 could directly target Chek1 for repression. A plasmid consisting of the Chek1 3ЈUTR linked to a constitutively active luciferase reporter was transfected into COS cells along with increasing amounts of miR-195 mimic. The Chek1 3ЈUTR luciferase reporter displayed a dose-dependent repression in activity by miR-195 ( Figure  4C ). Mutation of the miR-195 target site abolished repression by miR-195, which demonstrates that this effect was dependent on binding of miR-195 to its target site within the 3ЈUTR of Chek1 (Figure 4C ). 
Postnatal Inhibition of the miR-15 Family In Vivo Induces Cardiomyocyte Mitotic Entry
To further interrogate the potential role of the miR-15 family in suppression of cardiomyocyte proliferation, we knocked down the miR-15 family in vivo in neonatal mice using LNA-modified oligonucleotides directed against miR-15b and miR-16 (Online Table II ). Control mice received an oligonucleotide directed against an miRNA specific for C. elegans that is not present in mammals. To prevent postnatal upregulation of the miR-15 family, neonatal mice received anti-miRs (25 mg/kg) directed against the miR-15 family members miR-15b (anti-15) and miR-16 (anti-16) via subcutaneous injection once per day from P2 through P4 ( Figure 5A ). Initial pilot studies indicated that administration of either anti-15 or anti-16 alone was not sufficient to knock down expression of all miR-15 family members in the heart (Online Figure X, A) . However, when anti-15 and anti-16 (anti-15/16) were administered in combination (25 mg/kg each), we observed significant repression of all miR-15 family members in the heart at P12 (ie, 10 days after the first treatment; Online Figure IX, A) . Therefore, experimental animals received a combination of anti-15/16 delivered via subcutaneous injection between P2 and P4 and were harvested at P12 for confirmation of miRNA knockdown and assessment of target regulation and cardiomyocyte proliferation ( Figure 5A ). Successful knockdown of all miR-15 family members was achieved by this strategy, documented by Northern blot (Online Figure X, B) and quantified by real-time PCR ( Figure 5B ).
Postnatal inhibition of miR-15 family function was associated with an increased number of cardiomyocytes that stained positive for phospho-histone H3 ( Figure 5C ), as well as a higher number of cardiomyocytes that displayed disorganized sarcomeric structures (Online Figure XI, A and B) , which is characteristic of cardiomyocytes undergoing mitosis. 22 Cardiomyocyte size was unaffected by postnatal knockdown of the miR-15 family (Online Figure XI, C and D) . Importantly, 3 of 5 predicted miR-15 family targets from our RISC-seq studies were enhanced by miR-15 family knockdown, including the highly conserved target Chek1 ( Figure  5D ), as well as the nonconserved targets Cdc2a and Spag5 (Online Figure XII) . Although these data imply that postnatal inhibition of the miR-15 family increases cardiomyocyte mitotic entry and progression, we detected very few cardiomyocytes that stained positive for Aurora B kinase at P12 in control and anti-15/16 -treated groups (data not shown), which suggests that loss of miR-15 family function was not sufficient to drive complete mitotic progression through cytokinesis. Taken together, the present data suggest that postnatal upregulation of the miR-15 family may represent an important regulatory brake on the cardiomyocyte mitotic machinery, which contributes to postnatal cell cycle withdrawal.
Discussion
Here, we describe a group of miRNAs belonging to the miR-15 family that are upregulated after birth and that contribute to cardiomyocyte mitotic arrest during the neonatal period. Overexpression of miR-195 in the developing heart is associated with a spectrum of congenital cardiac abnormalities and premature cell cycle arrest. We provide evidence that miR-195 regulates a number of cell cycle genes in vivo, including Chek1. Postnatal inhibition of the miR-15 family in neonatal mice is associated with an increased number of mitotic cardiomyocytes and elevated expression levels of Chek1. The present study identifies a novel role for miRNAs in regulating cardiomyocyte mitotic arrest during early postnatal life, and a proposed model to account for the role of the miR-15 family in this process is outlined in Figure 6 .
The present data support previous studies in which miR-15 family members were found to inhibit cell proliferation. The miR-15a/16-1 cluster is located within the chromosomal region 13q14, which is commonly deleted or downregulated in chronic lymphocytic leukemia. 23 Genetic deletion of miR- 15a/16-1 in the mouse accelerates proliferation of B cells and contributes to the development of chronic lymphocytic leukemia. 24 The miR-15 family also appears to repress cell proliferation in a number of nonlymphoid cell systems, and deletion or downregulation of miR-15 family members is associated with the pathogenesis of a number of solid tumors. [25] [26] [27] [28] The present study is the first to implicate the miR-15 family in the physiological regulation of the cardiac cell cycle. Although the role of miR-15 family members in the developmental regulation of postnatal proliferative growth arrest in other tissues has not been assessed, it is probable that the miR-15 family also exerts tumor suppressor activity in multiple adult tissues. Given that the systemic anti-miR administration protocol used in the present study is likely to have effects on multiple organ systems, it will be interesting to examine the relative myocyte-autonomous and nonautonomous effects of the miR-15 family in the future.
A plethora of proliferation-associated genes have been reported to be targeted by the miR-15 family. 24 -28 We used a nonbiased approach for in vivo identification of miR-15 family target genes in the heart of neonatal miR-195 transgenic mice using RISC-seq. 19 Several mitotic genes were enriched within the miR-195 RISCome, including a number of genes that contained predicted miR-15 family binding sites located within their 3ЈUTRs, but Chek1 was the only predicted cell cycle-associated gene with an miR-15 family binding site in its 3ЈUTR that is conserved in humans. Interestingly, many genes that were enriched within the miR-195 RISCome did not contain predicted miR-15 family binding sites within their 3ЈUTR, which could reflect potential binding to sites located within the 5ЈUTR, coding sequence, or introns of target transcripts, 29 or possibly secondary effects of miRNA overexpression. Future studies using RISC-seq approaches in combination with mRNA footprinting 29 will likely shed further light on the precise mechanisms of miRNA target recognition in vivo.
The present findings are consistent with earlier observations in mice lacking miR-15a/16-1 in which Chek1 levels were found to be elevated. 24 Chek1 plays a crucial role in the prevention of genomic instability and mediates the cellular response to DNA replication errors, DNA damage, and chromatin breaks. 30 Furthermore, Chek1 has been implicated in the regulation of mitosis and coordinates progression through the G2/M and spindle checkpoints, as well as chromosome segregation and cytokinesis. 30, 31 Of particular relevance to the present findings, Chek1 has been shown to translocate to the spindle midzone during anaphase and later accumulates at the cytokinetic midbody, where it is thought to regulate the Aurora B-mediated abscission checkpoint. 30, 31 Heterozygous genetic deletion of Chek1 in mouse primary mammary epithelial cells is linked to increased chromosome lagging, cytokinetic regression, and binucleation. 31 Thus, the developmental inactivation of Chek1 in the heart after birth, which we show is mediated at least in part by postnatal induction of the miR-15 family, may contribute to the onset of cardiomyocyte binucleation during the neonatal period. This is the first study to implicate the miR-15 family in heart development. Of particular interest, overexpression of miR-195 in the developing heart is associated with a number of congenital heart abnormalities, including ventricular septal defects and severe ventricular hypoplasia. Ventricular septal defects and ventricular hypoplasia are commonly observed in mouse models with cardiomyocyte proliferative defects. 12, 32, 33 Moreover, a number of cell cycle genes are dysregulated in human patients with ventricular septal defects and hypoplastic heart syndrome. 34, 35 The present findings suggest that fine-tuning of cardiac cell cycle genes by miRNAs may be an important regulatory component of cardiac development and congenital heart disease.
We previously reported that postnatal overexpression of miR-195 in the heart under the control of the ␣-MHC promoter resulted in pathological cardiac remodeling and heart failure. 17 Interestingly, the present study suggests that embryonic overexpression of miR-195 in the heart can also drive adult cardiac hypertrophy and dilation, as well as premature death. It is possible that the phenotype observed in ␣-MHC-miR-195 transgenic mice also has developmental origins, because the ␣-MHC transgene is turned on perinatally. 36 Indeed, premature cardiomyocyte binucleation and cardiac growth restriction during early life have been reported to precede the onset of pathological cardiac hypertrophy in several experimental models of heart disease. [37] [38] [39] Although a number of studies have identified adult cardiac pathologies in mice with congenital heart abnormalities, 12, 40 the potential contribution of developmental defects related to cell cycle control in the pathogenesis of adult human cardiomyopathies is not well understood.
The miR-15 family has been shown recently to lie downstream of the p53 tumor suppressor pathway. [41] [42] [43] Although the upstream signals for postnatal induction of the miR-15 family in the heart are currently unknown, it is tempting to speculate that the miR-15 family is an important downstream effector of a tumor suppressor network that is activated in the heart shortly after birth ( Figure 6 ). Further analysis of the cis regulatory elements and upstream signals responsible for postnatal upregulation of the miR-15 family may shed light on the molecular determinants of cardiomyocyte mitotic arrest and open new avenues to cardiomyocyte cell cycle reinduction for cardiac repair.
